Abstract 34P
Background
Social support is an important determinant of optimal care and maybe extended by community partners including non-governmental organizations to enhance the well-being of individuals living with cancer. We determined whether social support mediated the association between unmet needs and happiness in women with early breast cancer in a multiethnic Asian setting.
Methods
The study employed a hospital-based cross-sectional design that recruited 400 multiethnic patients newly diagnosed with early breast cancer in seven tertiary Malaysian hospitals. Study tools included Multi-dimensional Scale of Perceived Social Support, Needs Assessment Tool for Breast Cancer and Oxford, Happiness Questionnaire. Partial least square structural equation modelling was used to determine the mediating role of social support in the association between unmet needs and happiness.
Results
Participants comprised Malays (58.3%), followed by Chinese (26.8%), and Indians (12.3%). Two-thirds were recruited from Ministry of Health-owned hospitals, 20.5% from academic and 14.8% from private hospitals. A majority were diagnosed with stage II (32.3%) or stage III (30.0%) breast cancer at initial diagnosis. About 5.3% of participants reported to be unhappy, 5.8% somewhat unhappy, 8.3% rather unhappy, 30.3% somewhat happy, 28.7% rather happy, and 21.8% happy. A majority had moderate-level unmet supportive care needs (74%), with the highest level of unmet needs in the domains of information services (31.3%) and hospital appointments (30.3%). Sixty per cent reported a high level of social support. Unmet needs were found to have a negative and significant effect on happiness (f 2 =8.0%, β = −0.259, p < 0.001). Social support significantly, positively, and partially mediated the association between unmet needs and, with the p-values significant for both direct (p < 0.001) and indirect (p = 0.024) effects.
Conclusions
Social support plays an important role in bridging unmet needs and improving well-being of women with breast cancer. Study findings are expected to foster greater public-private partnerships in engaging communities to actively play a role in improving life after (breast) cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Ministry of Higher Education, Malaysia.
Disclosure
R. Kaur: Financial Interests, Personal, Speaker, Consultant, Advisor: Novartis, AstraZeneca, Pfizer, Roche,. M. Thiagarajan: Non-Financial Interests, Institutional, Leadership Role: Malaysian Oncological Society, President. N.F. Bt Abdul Satar: Financial Interests, Personal, Advisory Board: Novartis, Zuellig Pharma,Ipsen Pharma, Eisai, MSD Malaysia,Pfizer, Roche,; Financial Interests, Personal, Funding: KURA Oncology, Viracta Therapeutics, MSD Malaysia, Naluri Sdn Bhd; Financial Interests, Institutional, Principal Investigator: KURA Oncology, Viracta Therapeutics, MSD Malaysia, Naluri Sdn Bhd; Non-Financial Interests, Personal, Leadership Role: Project Lead for Cancer ECHO UM. A. Ali: Financial Interests, Personal, Invited Speaker: Roche, AstraZeneca. F.L.T. Chong: Financial Interests, Personal, Invited Speaker: Novartis, Roche,; Financial Interests, Personal and Institutional, Principal Investigator: Novartis, J&J. A.F. Abdul Aziz: Financial Interests, Personal, Invited Speaker: Roche; Non-Financial Interests, Institutional, Member of Board of Directors: National Cancer Society Malaysia; Non-Financial Interests, Institutional, Member: Fellow of College of Surgeons, Academy of Medicine Malaysia Member of Malaysian Oncological Society. C.H. Yip: Financial Interests, Personal, Advisory Board: AstraZeneca. N. Bhoo-Pathy: Financial Interests, Personal, Funding: Partial funding from Ministry of Higher Education. All other authors have declared no conflicts of interest.
Resources from the same session
112P - Optimal classification and treatment strategy based on technical and oncological futures in recurrence of colorectal liver metastases
Presenter: Kosuke Kobayashi
Session: Poster Display
Resources:
Abstract
113P - Phase I/II study of capecitabine(C)/oxaliplatin(O)/irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
Presenter: Kai Ou
Session: Poster Display
Resources:
Abstract
114P - The prognostic role of LAG-3 expression in metastatic colorectal cancer
Presenter: Yi-Hsuan Huang
Session: Poster Display
Resources:
Abstract
115P - Sidedness and survival of chemo-refractory metastatic colorectal cancer treated with lonsurf or regorafenib: A nationwide population-based study in Taiwan
Presenter: Meng-Che Hsieh
Session: Poster Display
Resources:
Abstract
116P - Burden and trends of colorectal cancer in high income Asia Pacific countries from 1990-2019 and its projections of deaths to 2040: A comparative analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
117P - Australasian real-world treatment selection and clinical outcomes for patients with left side (LS), RAS wildtype (RASwt) metastatic colorectal cancer (mCRC)
Presenter: Vanessa Wong
Session: Poster Display
Resources:
Abstract
119P - Neoadjuvant chemoradiotherapy in the mode of hypofractionation in locally advanced rectal cancer: Is it time to change standards of care?
Presenter: Abror Abdujapparov
Session: Poster Display
Resources:
Abstract
120P - Improved clinical outcomes with cetuximab maintenance therapy in left-sided RAS/BRAF wild-type metastatic colorectal cancer: A real-world study of Hunan cancer hospital
Presenter: Xiaolin Yang
Session: Poster Display
Resources:
Abstract
121P - Single-cell sequencing reveals the role of Treg cells with high expression of BIRC3 in regulating the progression of colorectal cancer
Presenter: Yuqiu Xu
Session: Poster Display
Resources:
Abstract
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract